United States

People: Seattle Genetics Inc (SGEN.OQ)

SGEN.OQ on NASDAQ Stock Exchange Global Select Market

18 Apr 2019
Change (% chg)

$-1.62 (-2.29%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Siegall, Clay 

Dr. Clay B. Siegall, Ph.D., is the Chairman of the Board, President, Chief Executive Officer of Seattle Genetics, Inc. Dr. Siegall co-founded Seattle Genetics in 1997. He has served as our Chief Executive Officer since November 2002, as our President since June 2000, as one of our directors since December 1997 and as our Board chairman since March 2004. Dr. Siegall also served as our Chief Scientific Officer from December 1997 until November 2002. Prior to co-founding Seattle Genetics, Dr. Siegall was with the Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 1997, most recently as a Principal Scientist. From 1988 to 1991, Dr. Siegall was a Staff Fellow/Biotechnology Fellow at the National Cancer Institute, National Institutes of Health. Dr. Siegall received a Ph.D. in Genetics from George Washington University and a B.S. in Zoology from the University of Maryland. In addition to Seattle Genetics, Dr. Siegall serves as a director of Ultragenyx Pharmaceutical Inc., Alder BioPharmaceuticals, Inc., and Mirna Therapeutics, Inc., all publicly-traded biotechnology companies. Dr. Siegall’s experience in founding and building Seattle Genetics is integral to our success and our mission. His scientific understanding along with his corporate vision and operational knowledge provide strategic guidance to our management team and the Board of Directors.

Basic Compensation

Total Annual Compensation, USD 1,821,650
Restricted Stock Awards, USD 3,561,060
Long-Term Incentive Plans, USD --
All Other, USD 3,233,630
Fiscal Year Total, USD 8,616,340

Options Compensation

  Quantity Market Value
Exercisable 882,708 578,125.00
Unexercisable 122,292 23,075.00
Exercised 187,926 9,006,280.00
Name Fiscal Year Total

Clay Siegall


Todd Simpson


Jean Liu


Darren Cline


Vaughn Himes


Felix Baker

As Of  30 Dec 2017